Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection

Technical Report · Mon Mar 21 00:00:00 EDT 2016

DOI:https://doi.org/10.2172/1242919· OSTI ID:1242919

Koizumi, Yoshiki ^[1]; Nakajim, Syo ^[2]; Ohash, Hirofumi ^[2]; Tanaka, Yasuhito ^[3]; Wakita, Takaji ^[4]; Perelson, Alan S. ^[5]; Iwami, Shingo ^[6]; Watashi, Koichi ^[7]

---

1. Kanazawa Univ. (Japan). School of Medicine
2. National Inst. of Infectious Diseases, Tokyo (Japan); Tokyo Univ. of Science, Chiba (Japan)
3. Nagoya City Univ. Graduate School of Medicinal Sciences (Japan)
4. National Inst. of Infectious Diseases, Tokyo (Japan)
5. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
6. Kyushu Univ. (Japan); Japan Science and Technology Agency (JST), Saitama (Japan). PRESTO
7. National Inst. of Infectious Diseases, Tokyo (Japan); Tokyo Univ. of Science, Chiba (Japan); Japan Science and Technology Agency (JST), Saitama (Japan)

Cell culture study combing a mathematical model and computer simulation quantifies the anti-hepatitis C virus drug efficacy at any concentrations and any combinations in preclinical settings, and can obtain rich basic evidences for selecting optimal treatments prior to costly clinical trials.

• Research Organization: Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
• Sponsoring Organization: USDOE; National Institutes of Health (NIH)
• DOE Contract Number: AC52-06NA25396
• OSTI ID: 1242919
• Report Number(s): LA-UR-16-21895
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
Biological Science